Company profile: NuView Life Sciences
1.1 - Company Overview
Company description
- Provider of medical imaging and diagnostic solutions leveraging the NV-VPAC1 peptide to target VPAC1 receptors for PET imaging and theranostic applications. Offers in vitro urine-based diagnostic kits for detecting prostate and bladder cancer, in vivo PET agents for diagnosing breast and prostate cancer, and peptide-guided delivery of isotopes (e.g., Copper-64 for imaging, Copper-67 for treatment).
Products and services
- NV-VPAC1: A custom-engineered peptide that targets VPAC1 receptors to diagnose and treat diverse cancers, enabling PET imaging and serving as a radioisotope delivery platform
- Theranostics: A dual-modality theranostic system using NV-VPAC1 to deliver Copper-64 for PET imaging and Copper-67 for targeted cancer treatment, integrating diagnostic imaging with therapy
- In Vivo Diagnostics: A PET-optimized in vivo imaging agent that diagnoses breast and prostate cancer using PET imaging during diagnostic scans
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to NuView Life Sciences
Juno Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage immunotherapies for the treatment of cancer, formed through a unique partnership with Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center, and Seattle Children’s Research Institute to advance a broad pipeline of breakthrough immunotherapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Juno Therapeutics company profile →
Azeria Therapeutics
HQ: United States
Website
- Description: Provider of small-molecule cancer drug development, creating a pipeline of therapies designed to selectively inhibit pioneer factors to aid treatment of breast and prostate cancer patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Azeria Therapeutics company profile →
GenomeDx
HQ: Canada
Website
- Description: Provider of genomic-based laboratory tests for personalized medicine in cancer care, including the Decipher Prostate Cancer Classifier for independent assessment of tumor aggressiveness, the Decipher GRID genomic expression database in urologic cancer, and genomic testing and a development pipeline focused on creating genomic tests for urologic cancers to aid personalized treatment decisions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GenomeDx company profile →
Neon Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies focused on neoantigen-targeted approaches to direct the immune system to recognize and attack cancer. Pipeline includes NEO-PV-01, NEO-PTC-01, and NEO-SV-01.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neon Therapeutics company profile →
Origo Biopharma
HQ: Spain
Website
- Description: Provider of research and development of immunotherapeutic products targeting health disorders related to TGF-beta signaling dysfunction, including cancer and fibrosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Origo Biopharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for NuView Life Sciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to NuView Life Sciences
2.2 - Growth funds investing in similar companies to NuView Life Sciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for NuView Life Sciences
4.2 - Public trading comparable groups for NuView Life Sciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →